MX2 is an interferon-induced inhibitor of HIV-1 infection

HIV-1 replication can be inhibited by type I interferon (IFN), and the expression of a number of gene products with anti-HIV-1 activity is induced by type I IFN. However, none of the known antiretroviral proteins can account for the ability of type I IFN to inhibit early, preintegration phases of the HIV-1 replication cycle in human cells. Here, by comparing gene expression profiles in cell lines that differ in their ability to support the inhibitory action of IFN-α at early steps of the HIV-1 replication cycle, we identify myxovirus resistance 2 (MX2) as an interferon-induced inhibitor of HIV-1 infection. Expression of MX2 reduces permissiveness to a variety of lentiviruses, whereas depletion of MX2 using RNA interference reduces the anti-HIV-1 potency of IFN-α. HIV-1 reverse transcription proceeds normally in MX2-expressing cells, but 2-long terminal repeat circular forms of HIV-1 DNA are less abundant, suggesting that MX2 inhibits HIV-1 nuclear import, or destabilizes nuclear HIV-1 DNA. Consistent with this notion, mutations in the HIV-1 capsid protein that are known, or suspected, to alter the nuclear import pathways used by HIV-1 confer resistance to MX2, whereas preventing cell division increases MX2 potency. Overall, these findings indicate that MX2 is an effector of the anti-HIV-1 activity of type-I IFN, and suggest that MX2 inhibits HIV-1 infection by inhibiting capsid-dependent nuclear import of subviral complexes.

[1]  G. Raposo,et al.  Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[3]  P. Bieniasz,et al.  Human immunodeficiency virus, restriction factors, and interferon. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[4]  A. Engelman,et al.  Flexible use of nuclear import pathways by HIV-1. , 2010, Cell host & microbe.

[5]  M. Emerman,et al.  Capsid Is a Dominant Determinant of Retrovirus Infectivity in Nondividing Cells , 2004, Journal of Virology.

[6]  Marc C. Johnson,et al.  Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly , 2006, PLoS biology.

[7]  W. Sundquist,et al.  Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid , 2004, Journal of Virology.

[8]  H. Ding,et al.  Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages , 2011, Journal of Virology.

[9]  M. Emerman,et al.  Cellular Restriction Targeting Viral Capsids Perturbs Human Immunodeficiency Virus Type 1 Infection of Nondividing Cells , 2009, Journal of Virology.

[10]  M. Emerman,et al.  Evidence for Direct Involvement of the Capsid Protein in HIV Infection of Nondividing Cells , 2007, PLoS pathogens.

[11]  A. Kingsman,et al.  Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.

[12]  R. Schooley,et al.  RECOMBINANT HUMAN INTERFERON ALFA-A SUPPRESSES HTLV-III REPLICATION IN VITRO , 1985, The Lancet.

[13]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[14]  P. Bieniasz,et al.  Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses , 2013, Journal of Virology.

[15]  P. Keskinen,et al.  Human MxB Protein, an Interferon-α-inducible GTPase, Contains a Nuclear Targeting Signal and Is Localized in the Heterochromatin Region beneath the Nuclear Envelope* , 1996, The Journal of Biological Chemistry.

[16]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[17]  P. Bieniasz,et al.  Restriction of multiple divergent retroviruses by Lv1 and Ref1 , 2003, The EMBO journal.

[18]  S. Antonarakis,et al.  TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm , 2013, Retrovirology.

[19]  M. Malim,et al.  Characterization of the Alpha Interferon-Induced Postentry Block to HIV-1 Infection in Primary Human Macrophages and T Cells , 2010, Journal of Virology.

[20]  Mahdad Noursadeghi,et al.  HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency , 2011, PLoS pathogens.

[21]  Kevin C. Olivieri,et al.  Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection , 2013, Retrovirology.

[22]  E. Poeschla,et al.  Mapping the Encapsidation Determinants of Feline Immunodeficiency Virus , 2002, Journal of Virology.

[23]  Jeremy Luban,et al.  Target Cell Cyclophilin A Modulates Human Immunodeficiency Virus Type 1 Infectivity , 2004, Journal of Virology.

[24]  J. Stoye Fv1, the mouse retrovirus resistance gene. , 1998, Revue scientifique et technique.

[25]  Charles M. Rice,et al.  Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response , 2015, Nature.

[26]  C. Aiken,et al.  Evidence for a Functional Link between Uncoating of the Human Immunodeficiency Virus Type 1 Core and Nuclear Import of the Viral Preintegration Complex , 2006, Journal of Virology.

[27]  G. Kochs,et al.  Interferon-induced Mx proteins in antiviral host defense. , 2007, Biochimie.

[28]  Kenneth A. Matreyek,et al.  Differential Effects of Human Immunodeficiency Virus Type 1 Capsid and Cellular Factors Nucleoporin 153 and LEDGF/p75 on the Efficiency and Specificity of Viral DNA Integration , 2012, Journal of Virology.

[29]  Kathryn L. Parsley,et al.  In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium , 2001, Gene Therapy.